Marike Knoef Appointed to DNB Supervisory Board

De Nederlandsche Bank (DNB) announces the appointment of Professor Marike Knoef to its Supervisory Board effective 1 April 2026. Knoef, Dean of the Tilburg School of Economics and Management, replaces Mirjam van Praag who stepped down on 1 March 2026. The appointment was made by Finance Minister Eelco Heenen for an initial four-year term.

Q1 2026 Healthcare Consolidation Legislation Recap

Holland & Knight's Q1 2026 recap summarizes proposed federal and state legislation affecting healthcare consolidation. Key federal developments include the successful challenge to FTC's Hart-Scott-Rodino rules (returning to old rules pending appeals) and FTC Chair's March 20, 2026 memorandum establishing a Healthcare Task Force. State legislatures have expanded scrutiny beyond private equity to include REITs, MSOs, and health insurers, with states revisiting corporate practice of medicine doctrine. Of 12 tracked bills, only 2 passed while 10 stalled.

Canada Launches Pharmaceutical and Life Sciences Sector Task Force

Health Canada and Innovation, Science and Economic Development Canada announced the creation of the Pharmaceutical and Life Sciences Sector Task Force on March 18, 2026. The joint initiative will explore made-in-Canada solutions to enhance competitiveness and improve access to pharmaceutical products while reducing regulatory burden. The task force builds on Health Canada's ongoing Red Tape Review and will include pharmaceutical and biotechnology stakeholders.

Healthcare Regulatory Update: CMS Claims Rule, Reconciliation, Illicit Drug Legislation

McDermott+ Consulting weekly update covering CMS final rule modernizing claims processing with HIPAA standards for electronic healthcare claims attachments and electronic signatures. Congressional Republicans are discussing 'reconciliation 2.0' legislation with potential healthcare savings; House Energy and Commerce Health Subcommittee reviewed opioid-related bills including the Combatting Illicit Xylazine Act and Alternatives to Pain Act. HHS announced new Healthcare Advisory Committee members and launched the ASPIRE pediatric care coordination model.

Tennessee gets $206.9M rural healthcare transformation funding

Tennessee gets $206.9M rural healthcare transformation funding

AI Scribe Legal Risks, Consent Requirements, HIPAA Compliance

JD Supra Healthcare published a legal analysis by McDermott Will & Schulte addressing legal considerations for healthcare providers deploying AI scribes. The article covers state recording consent laws (noting over a dozen all-party consent states), HIPAA implications, biometric consent issues related to voiceprint features, and vendor liability considerations for third-party AI platforms.

CMS Nationwide DMEPOS Enrollment Moratorium - Seven Supplier Types

CMS announced a six-month nationwide enrollment moratorium on initial Medicare enrollment for seven categories of DMEPOS suppliers, effective February 27, 2026 through August 27, 2026. The moratorium, the first nationwide DMEPOS enrollment freeze in program history, targets medical supply companies with orthotics, pedorthic, prosthetics, and other specialized personnel. Florida became the first state to implement a parallel Medicaid DMEPOS moratorium on March 25, 2026, signaling potential expansion to other states.

FTC Healthcare Task Force targets consolidation, enforcement authority boost

FTC Healthcare Task Force targets consolidation, enforcement authority boost

Trademark Application - Rejuvenation Wellness (Class 044)

USPTO received an Intent to Use trademark application TM98206553 for 'REJUVENATION WELLNESS' covering wellness services, health-related consulting, health spa services, and dietary supplements in Class 044. The application was filed on October 2, 2023, establishing priority rights for the mark. No opposition period or compliance deadlines are specified for third parties.

Prostate Intelliscore Medical Diagnostic Trademark Application

The USPTO received a trademark application (TM99033032) for 'Prostate Intelliscore' on February 7, 2025, filed under Intent to Use provisions. The application covers medical testing services, liquid biopsy testing, and diagnostic kits for disease detection including cancer. This is a routine trademark registration filing with no immediate regulatory obligations for other parties.